VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib

BACKGROUND: Currently, sunitinib represents one of the therapeutic strongholds for renal cell carcinoma, but the criteria for treatment selection are lacking. We assessed the role of vascular endothelial growth factor (VEGF) and VEGF receptor (VEGFR) polymorphisms in the prediction of the clinical o...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Scartozzi, M, Bianconi, M, Faloppi, L, Loretelli, C, Bittoni, A, Del Prete, M, Giampieri, R, Maccaroni, E, Nicoletti, S, Burattini, L, Minardi, D, Muzzonigro, G, Montironi, R, Cascinu, S
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2013
Matèries:
Molecular Diagnostics
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3619056/
https://ncbi.nlm.nih.gov/pubmed/23511629
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2012.501
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars